NCT06154902View on ClinicalTrials.gov

Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel

Active, not recruitingOBSERVATIONAL
Enrollment

350

Participants

Timeline

Start Date

July 29, 2022

Primary Completion Date

July 31, 2027

Study Completion Date

December 31, 2027

Conditions
Multiple Myeloma
Interventions
DRUG

Idecabtagene vicleucel

According to approved product label in France

OTHER

Not treated

Eligible for idecabtagene vicleucel treatment but not treated

Trial Locations (1)

Unknown

DESCAR-T Registry, Paris

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY